{"entity":{"id":"nct07459634","kind":"trial","name":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC","aka":[],"tldr":"A phase 2 trial of Lurbinectedin, Durvalumab in small-cell lung cancer, run by Jazz Pharmaceuticals, now recruiting.","summary":"A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC is a phase 2 interventional study registered as NCT07459634 by Jazz Pharmaceuticals, with 50 participants planned, started 2026-11-30 and due to reach its primary completion in 2028-01-31. Interventions recorded: Lurbinectedin, Durvalumab. Conditions listed: Extensive-stage Small-cell Lung Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07459634","url":"https://clinicaltrials.gov/study/NCT07459634"}],"tags":["ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["lurbinectedin","durvalumab"],"companies":["jazz"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07459634","phase":"2","setting":"A Phase 2, Multicenter, Open-Label, Single-Arm Study of Lurbinectedin in Combination With Durvalumab as First-line Maintenance Therapy in Participants With Extensive-Stage Small-Cell Lung Cancer Following Induction Treatment With Platinum Based Chemotherapy and Durvalumab","sponsor":"Jazz Pharmaceuticals","enrolled":50,"outcomes":[]},"route":"/trials/nct07459634/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"lurbinectedin","kind":"drug","name":"Lurbinectedin","route":"/drugs/lurbinectedin/"}],"company":[{"id":"jazz","kind":"company","name":"Jazz Pharmaceuticals","route":"/companies/jazz/"}]}}